Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EMD249590 + molgramostim
- Development stage
- Discontinued
- Lead developer
- Norsk Hydro
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous (for Vaccine Component; Typical For Peptide/protein Vaccines), Inhalation Or Subcutaneous (molgramostim Can Be Administered By Inhalation Or Injection; In Oncology Trials Often Subcutaneous)
01
Overview
EMD249590 + molgramostim is an investigational combination therapy consisting of a Ras cancer vaccine (EMD249590) and molgramostim. - **EMD249590** is a therapeutic cancer vaccine developed to target the Ras oncogene pathway. It acts as an inhibitor of synaptic Ras GTPase activating protein 1 (SYNGAP1), aiming to elicit an immune response against tumors with activated Ras signaling[2]. - **Molgramostim** is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF). It stimulates the growth and activation of macrophages and other immune cells, enhancing the body’s immune response[6][9]. In this combination, it likely serves as an immunological adjuvant to boost the efficacy of the cancer vaccine.
- Other names
- Ras cancer vaccine + molgramostim
02
Targets
CSF2R (Granulocyte-macrophage colony-stimulating factor receptor)
Beyond the preview
Go deeper on EMD249590 + molgramostim.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EMD249590 + molgramostim.